FDA Determines Semaglutide Injection Shortage Resolved
2025-02-21
FDA confirms semaglutide injection shortage is resolved as manufacturer capacity meets national demand. Other GLP-1 products remain under monitoring.
The U.S. Food and Drug Administration has determined that the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Semaglutide injection products had been in shortage since 2022 due to increased demand.
The FDA confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand. However, patients and prescribers may still see intermittent and limited localized supply disruptions as products move through the supply chain.
The agency continues to actively monitor the availability of other GLP-1 products including liraglutide injection, which remains in shortage with limited availability across certain presentations.
Read Full Source Article